Efficacy of Double Bronchodilation (LABA + LAMA) in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer;Análisis de la eficacia de la doble broncodilatación (LABA + LAMA) en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y cáncer de pulmón

Archivos de Bronconeumologia

Volumn 52, Issue 12, 2016, Pages 622-623

  Leiro Fernández, Virginia ^a   Priegue Carrera, Ana ^a   Fernández Villar, Alberto ^a  

^a Hospital Alvaro Cunqueiro   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; LONG ACTING DRUG; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLYCOPYRRONIUM; INDACATEROL; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE; ACLIDINIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE; OLODATEROL; SALMETEROL; TIOTROPIUM BROMIDE; VILANTEROL;

ARTICLE; BRONCHODILATATION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; LUNG CANCER; ADENOCARCINOMA; AGED; CLINICAL TRIAL; COMPLICATION; DELAYED RELEASE FORMULATION; FEMALE; LUNG RESECTION; LUNG TUMOR; MALE; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; ADULT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COMBINATION CHEMOTHERAPY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; LUNG FUNCTION; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADENOCARCINOMA; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; CARCINOMA, SQUAMOUS CELL; DELAYED-ACTION PREPARATIONS; FEMALE; GLYCOPYRROLATE; HUMANS; INDANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PILOT PROJECTS; PNEUMONECTOMY; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 85027218745     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2016.05.018     Document Type: Article

References (5)

1. 1 Durham, A.L., Adcock, I.M., The relationship COPD and lung cancer. Lung Cancer 90 (2015), 121–127.
2. 2 Brunelli, A., Kim, A.W., Berger, K.I., Addrizzo-Harris, D.J., Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:5 Suppl (2013), e166S–e190S.
3. 3 Hashimoto, N., Matsuzaki, A., Okada, Y., Imai, N., Iwano, S., Wakai, K., et al. Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients. BMC Pulm Med, 14, 2014, 14.
4. 4 Bölükbas, S., Eberlein, M., Eckhoff, J., Schirren, J., Short-term effects of inhalative tiotropium/formoterol/budesonide versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: A prospective randomized trial. Eur J Cardiothorac Surg 39 (2011), 995–1000.
5. 5 Kobayashi, S., Suzuki, S., Nikawa, H., Sugawara, T., Yanai, M., Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. Respirology 14 (2009), 675–679.